Cambrex Completes Acquisition of Halo Pharma

Sep 18, 2018
By Pharmaceutical Technology Editors

Cambrex, a manufacturer of small-molecule innovator and generic APIs, announced on Sept. 12, 2018 that it has acquired Halo Pharma, a dosage form contract development and manufacturing organization (CDMO) located in Whippany, NJ and Mirabel, Québec, Canada, for approximately $425 million.

The transaction, previously announced in July 2018, adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network. The Whippany and Mirabel sites provide formulation development and clinical and commercial manufacturing services, specializing in oral solids, liquids, creams, sterile, and non-sterile ointments. Cambrex reports that the facilities’ core competencies include developing and manufacturing highly complex and difficult-to-produce formulations, products for pediatric indications, and controlled substances.

“The acquisition is well-aligned with our commitment to providing best-in-class services to meet the needs of our global pharmaceutical, biotech and generic customers and the combined business creates a leading small molecule CDMO with both API and finished dosage development and manufacturing capabilities,” commented Steve Klosk, president and CEO of Cambrex, in a company press release.

“This acquisition expands our manufacturing footprint with the addition of two state-of-the art, GMP-compliant manufacturing facilities in North America, both with a strong reputation for quality and excellent track records with regulatory approvals from FDA, Europe, the Middle East, Africa, [United States] Drug Enforcement Administration, and Health Canada,” said Shawn Cavanagh, COO of Cambrex, in the company press release. “We look forward to welcoming the 450-person workforce in joining our existing 1200 experts across the United States and Europe and to continue to build long-term partnerships with our customers.”

Source: Cambrex

lorem ipsum